Post-Hoc Live
Post-Hoc Live
Podcast Description
Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations.
Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: [email protected]
Podcast Insights
Content Themes
The show covers critical themes in the biopharmaceutical industry including the implications of evolving AI technologies on drug development, vaccination policy and political influences on public health as exemplified by the discussions on the ACIP board, and sentiment analysis in biotechnology. Episodes have featured discussions on President Trump's drug pricing plans and the reaction of the pharma industry to significant political developments, such as his tariffs on pharmaceutical products.
Post-Hoc Live is an extension of Endpoints’ analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We’re bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations.
Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: [email protected]
Last week, the U.S. International Trade Commission said it would investigate whether US biotech companies were at an unfair disadvantage because of Chinese pricing practices. The move was one of the many recommendations made by the National Security Commission on Emerging Biotechnology, which has spent the past year taking a close look at the rise of China’s biotech industry. Friday on the show, Endpoints reporters Max Bayer and Zach Brennan will talk with NSCEB Executive Director Caitlin Frazer about the group’s slate of proposals and the role policy changes can play in shoring up US biotech.
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.